Text Size
11 studies found for:    GSK1265744

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 Oral;   Drug: GSK1265744 LAP 800mg intramuscular injection;   Drug: GSK1265744 LAP 200mg subcutaneous injection;   Drug: GSK1265744 LAP 200mg intramuscular injection;   Drug: GSK1265744 LAP 400mg intramuscular injection;   Drug: TMC278 LA 1200mg intramuscular injection;   Drug: TMC278 LA 600mg intramuscular injection
2 Not yet recruiting An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects
Condition: HIV-associated Lipodystrophy Syndrome
Interventions: Drug: GSK1265744B (sodium salt) containing 14C-GSK1265744B;   Drug: 150 mg GSK1265744B;   Drug: Placebo
3 Active, not recruiting Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
4 Recruiting A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 30 mg oral;   Drug: Midazolam 3 mg oral + GSK1265744 30mg oral;   Drug: GSK1265744 400 mg (200 nm);   Drug: GSK1265744 400 mg (1 micro m);   Drug: GSK1265744 400 mg (5 micro m)
5 Completed Relative Bioavailability Study of GSK1265744 Formulations
Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: GSK1265744 Na Salt Tablets;   Drug: GSK1265744 Free Acid Nanomilled Capsules;   Drug: GSK1265744 Free Acid Micronized Capsules
6 Completed Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.
Conditions: HIV Infection;   Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg oral solution;   Drug: GSK1265744 5 mg tablet
7 Completed Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Condition: Acquired Immunodeficiency Syndrome
Interventions: Drug: GSK1265744;   Drug: Placebo
8 Completed A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: GSK1265744 injectable suspension;   Other: Placebo to match injectable suspension
9 Completed A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects
Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: Dolutegravir;   Drug: Rlipivirine;   Drug: GSK1265744
10 Completed A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744
Condition: HIV Infection
Intervention: Drug: GSK1265744
11 Completed DDI Study of Etravirine and GSK1265744
Conditions: Healthy Subjects;   Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK1265744
To Top

† Indicates status has not been verified in more than two years